A hormone released by the intestine after eating. It prompts glucose-dependent insulin release, slows gastric emptying, and signals to appetite centres in the brain.

What is the incretin effect?

Glucose taken by mouth produces far more insulin release than the same amount injected into a vein, because the gut sends advance warning that food is arriving. GLP-1 is part of that warning system.

Why did it take so long to make a drug from GLP-1?

Because natural GLP-1 is destroyed within about two minutes by the enzyme DPP-4. Every compound in this family is fundamentally a solution to that durability problem.

How is Cagrilintide different from the rest?

It is an amylin analogue acting on an entirely separate receptor system rather than an incretin receptor, which is why it is studied in combination with semaglutide rather than against it.

Does more receptors mean better?

Not automatically. More receptors means a broader mechanism and more variables — and the compounds with the most receptors currently have the least long-term human data behind them.

Research Library›Metabolic Research›The GLP-1 Family Explained

Category Overview

The GLP-1 Family Explained: One Gut Hormone and Everything Built From It

Every compound in this category descends from a single hormone your intestine releases after a meal. Understanding that hormone explains the whole family.

8 min read·4 studies cited·Updated July 2026

Quick Reference

Category	Incretin / metabolic compounds
Founding hormone	GLP-1, released by the gut after eating
The problem it solved	Natural GLP-1 lasts about two minutes
Compounds covered	Semaglutide, Tirzepatide, Retatrutide, Cagrilintide and others
Status	Research use only

The Hormone It All Starts From

GLP-1 — glucagon-like peptide-1 — is released by the intestine when food arrives. It does several things at once: prompts insulin release, but only when blood glucose is already elevated; slows the stomach emptying; and signals to appetite centres in the brain.

The incretin effect, in plain language: here is an odd fact that took researchers decades to explain. Give someone glucose by mouth, and they release considerably more insulin than if you inject the identical amount of glucose straight into a vein. Same sugar, same amount, in the bloodstream either way — but the mouth route produces a much bigger response. The reason is that the gut sees food coming and sends advance warning. It is the difference between a kitchen being told an order is on its way and a kitchen discovering a customer already seated. GLP-1 is part of that warning system, and the whole category is built on it.

The Engineering Problem

Natural GLP-1 is destroyed within roughly two minutes by an enzyme called DPP-4. That brevity is why the hormone was understood long before anything useful could be made from it — a signal that lasts two minutes is not a treatment.

Every compound in this family is, at heart, a solution to that one problem. Exenatide, the first of the class, came from a lizard peptide naturally resistant to the enzyme. Liraglutide and then semaglutide attached fatty acid chains so the molecule binds albumin in the blood and escapes rapid clearance — turning two minutes into about a week.

Then They Started Adding Receptors

Once duration was solved, the field turned to combinations. Tirzepatide added GIP, the other major incretin, and outperformed single-agonist compounds. Survodutide and Mazdutide pair GLP-1 with glucagon instead. Retatrutide engages all three.

Cagrilintide sits outside this logic entirely: it is an amylin analogue acting on a separate receptor system, which is why it is studied in combination with semaglutide rather than as a competitor to it.

The consistent pattern worth remembering is that the compounds with the most receptors have the least long-term human data. Semaglutide has years of post-approval evidence; retatrutide has promising Phase 2 results and open questions.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Drucker DJ. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell metabolism, 2018. PubMed
Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Frontiers in endocrinology, 2019. PubMed
Nauck MA, Meier JJ. “Incretin hormones: Their role in health and disease.” Diabetes, obesity & metabolism, 2018. PubMed
Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.” The New England journal of medicine, 2023. PubMed